Clinical Trial Update: Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of nab-paclitaxel plus gemcitabine for recurrent or refractory sarcoma has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Osteosarcoma
• Rhabdomyosarcoma
• Soft Tissue Sarcoma

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Gemzar (gemcitabine)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Osteosarcoma, Ewing Sarcoma | Phase 2 | Status: COMPLETED | Results posted: 2025-12-01